Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01586195
Title Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Genentech
Indications

melanoma

Therapies

Vemurafenib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Arizona Cancer Center Tucson Arizona 85724 United States Details
UCSD Moores Cancer Center La Jolla California 92093 United States Details
UCLA School of Medicine; Hematology/Oncology Los Angeles California 90095 United States Details
The Angeles Clinic and Research Institute, Santa Monica Office Santa Monica California 90025 United States Details
University of Colorado; Anschutz Cancer Pavilion Aurora Colorado 80045 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Emory University; Winship Cancer Institute Atlanta Georgia 30308 United States Details
Oncology Specialists, S.C. Park Ridge Illinois 60068 United States Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
Atlantic Health System Morristown New Jersey 07960 United States Details
Columbia University Medical Center New York New York 10032 United States Details
Mid Ohio Onc Hematology Inc Columbus Ohio 43219 United States Details
UPCI Cancer Institute; Cancer Pavillion Pittsburgh Pennsylvania 15232 United States Details
Vanderbilt Univ Medical Ctr Nashville Tennessee 37232 United States Details
Texas Oncology-Baylor Sammons Cancer Center Dallas Texas 75246 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field